[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367444-105":59,"doc-detail-367444-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","combinational-therapeutic-strategies-to-overcome-resistance-to-immune-checkpoint-inhibitors-review","Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors - review","","Immune checkpoint inhibitors (ICIs) have delivered remarkable, durable outcomes in cancer treatment, yet only a minority of patients achieve favorable responses due to diverse tumor-intrinsic and tumor-extrinsic resistance mechanisms. This review synthesizes emerging combination strategies that target resistance by boosting tumor immunogenicity, strengthening neoantigen processing and presentation, and enhancing T-cell infiltration and cytotoxic activity. Clinical evidence also reflects improved survival and tumor growth control alongside precision-medicine needs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/combinational-therapeutic-strategies-to-overcome-resistance-to-immune-checkpoint-inhibitors-review/367444/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/combinational-therapeutic-strategies-to-overcome-resistance-to-immune-checkpoint-inhibitors-review/367444.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do only some patients respond to immune checkpoint inhibitors?","Question",{"text":112,"@type":113},"Responses are limited because resistance arises from multiple interconnected tumor-intrinsic and tumor-extrinsic factors, affecting how the therapy can stimulate effective anti-tumor immunity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What tumor-intrinsic mechanisms contribute to resistance?",{"text":117,"@type":113},"The review highlights inadequate neoantigens, impaired antigen processing and presentation, altered oncogenic signaling, and epigenetic changes that promote drug resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"How do combination therapies aim to overcome resistance to ICIs?",{"text":121,"@type":113},"They seek to enhance tumor immunogenicity and neoantigen processing, improve antigen presentation, increase T-cell infiltration, and raise cytotoxic potential, which can translate into better clinical outcomes such as survival and tumor growth control.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367444,1790318945,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Review  \nPUBLISHED 24 April 2025  \nDOI 10.3389/fimmu.2025.1546717  \nOPEN ACCESS  \nEDITED BY  \nAndrea Lada´ nyi,  \nNational Institute of Oncology (NIO), Hungary  \nREVIEWED BY  \nDipendra Khadka,  \nNADIANBIO Co. Ltd. Wonkwang University School of Medicine, Republic of Korea Santenna Chenchula,  \nAll India Institute of Medical Sciences, India  \n*CORRESPONDENCE  \nBassam R. Ali  \n [bassam.ali@uaeu.ac.ae](bassam.ali@uaeu.ac.ae)[ ](bassam.ali@uaeu.ac.ae)Eyad Elkord  \n [Eyad.Elkord@xjtlu.edu.cn](Eyad.Elkord@xjtlu.edu.cn)  \nRECEIVED 17 December 2024  \nACCEPTED 31 March 2025  \nPUBLISHED 24 April 2025  \nCORRECTED 24 April 2026  \nCITATION  \nAlsaafeen BH, Ali BR and Elkord E (2025)  \nCombinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors.  \nFront. Immunol. 16:1546717 .  \ndoi: 10.3389/fimmu.2025.1546717  \nCOPYRIGHT  \n© 2025 Alsaafeen, Ali and Elkord. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCombinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors  \nBesan H. Alsaafeen 1,2, Bassam R. Ali 1,2* and Eyad Elkord 3,4,5*  \n1 Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates, 2ASPIRE Precision Medicine Research Institute Abu Dhabi, United Arab Emirates University, Al Ain, United Arab Emirates, 3 Department of Biosciences and Bioinformatics & Suzhou Municipal Key Lab of Biomedical Sciences and Translational Immunology, School of Science, Xi’an Jiaotong-Liverpool University, Suzhou, China, 4College of Health Sciences, Abu Dhabi University, Abu Dhabi, United Arab Emirates, 5 Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Manchester, United Kingdom  \nOver the past few years, immune checkpoint inhibitors resulted in magniﬁcent and durable successes in treating cancer; however, only a minority of patients respond favorably to the treatment due to a broad-spectrum of tumor-intrinsic and tumor-extrinsic factors. With the recent insights gained into the mechanisms of resistance, combination treatment strategies to overcome the resistance and enhance the therapeutic potential of immune checkpoint inhibitors are emerging and showing promising results in both pre-clinical and clinical settings. This has been derived through multiple interconnected mechanisms such as enhancing tumor immunogenicity, improving neoantigen processing and presentation in addition to augmenting T cell inﬁltration and cytotoxic potentials. In the clinical settings, several avenues of combination treatments involving immune checkpoint inhibitors were associated with considerable improvement in the therapeutic outcome in terms of patient’s survival and tumor growth control. This, in turn, increased the spectrum of cancer patients beneﬁting from the unprecedented and durable effects of immune checkpoint inhibitors leading to their adoption as a ﬁrst-line treatment for certain cancers. Moreover, the signiﬁcance of precision medicine in cancer immunotherapy and the unmet demand to develop more personalized predictive biomarkers and treatment strategies are also highlighted in this review.  \nKEYWORDS  \nimmune checkpoint inhibitors, resistance, combination, precision immunotherapy, tumor mircoenvironment  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nThe past decade has witnessed signiﬁcant advancements with the use of immune checkpoint inhibitors (ICIs) in treating certain cancers (1) . Unlike traditional cancer treatment modalities that f","cbCaiqXzQk7kEkl0","https://ap.wps.com/l/cbCaiqXzQk7kEkl0","pdf",2323415,17,"English","# Introduction\n# Resistance mechanisms to ICIs\n## Tumor-intrinsic factors\n## Tumor-extrinsic factors\n# Rationale for combination strategies","[{\"question\":\"Why do only some patients respond to immune checkpoint inhibitors?\",\"answer\":\"Responses are limited because resistance arises from multiple interconnected tumor-intrinsic and tumor-extrinsic factors, affecting how the therapy can stimulate effective anti-tumor immunity.\"},{\"question\":\"What tumor-intrinsic mechanisms contribute to resistance?\",\"answer\":\"The review highlights inadequate neoantigens, impaired antigen processing and presentation, altered oncogenic signaling, and epigenetic changes that promote drug resistance.\"},{\"question\":\"How do combination therapies aim to overcome resistance to ICIs?\",\"answer\":\"They seek to enhance tumor immunogenicity and neoantigen processing, improve antigen presentation, increase T-cell infiltration, and raise cytotoxic potential, which can translate into better clinical outcomes such as survival and tumor growth control.\"}]","Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors - review | PDF",1790170822,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e9e9060d22901cbefeeae45aa49961e.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58407fec4c0cfdf508bdc4f870eb19e9.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b73609eddaf0363494c82ac49c2cf704.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f86a978160ff66226163d257d31827f7.webp",980,1385]